Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial.

Abstract

PURPOSE A phase III randomized trial was performed to determine whether combination hormonal therapy with aminoglutethimide (AG) and hydrocortisone (HC) plus megestrol acetate (MA) improved response rates, response duration, or increased survival over the sequential use of each hormone in women with estrogen receptor-positive metastatic breast cancer (MBC… (More)

Topics

Cite this paper

@article{Russell1997MegestrolAA, title={Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial.}, author={Christy Ann Russell and Sandra Green and Jacintha O'sullivan and Harry E. Hynes and George Thomas Budd and Jacob Congdon and Silvana Martino and Charles Kent Osborne}, journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology}, year={1997}, volume={15 7}, pages={2494-501} }